Pacira BioSciences (PCRX) EBT Margin (2010 - 2026)

Pacira BioSciences' EBT Margin history runs 17 years deep, the most recent figure standing at 2.82% for Q1 2026.

• On a quarterly basis, EBT Margin fell 234.0% year-over-year to 2.82% in Q1 2026; TTM through Mar 2026 was 1.79%, a 1147.0% increase from a year earlier, with the FY2025 full-year figure at 2.32%, up 1133.0% from the prior year.
• EBT Margin rose to 2.82% in Q1 2026 per PCRX's latest filing, from 0.29% in the prior quarter.
• Across five years, EBT Margin topped out at 22.34% in Q2 2023 and bottomed at 82.37% in Q3 2024.
• The 5-year median for EBT Margin is 5.15% (2025), against an average of 1.74%.
• Across the five-year window, EBT Margin slumped 9250 bps in 2024 and jumped 8768 bps in 2025, its largest moves.
• Year by year, EBT Margin stood at 3.67% in 2022, then soared by 407 bps to 18.6% in 2023, then decreased by 27 bps to 13.63% in 2024, then slumped by 98 bps to 0.29% in 2025, then jumped by 872 bps to 2.82% in 2026.
• Per Business Quant, the three latest PCRX EBT Margin figures stand at 2.82% (Q1 2026), 0.29% (Q4 2025), and 5.31% (Q3 2025).